Literature DB >> 26162564

Second line therapy in malignant pleural mesothelioma: A systematic review.

Wieneke A Buikhuisen1, Birgitta I Hiddinga2, Paul Baas1, Jan P van Meerbeeck3.   

Abstract

After the implementation of standard first line chemotherapy with platinum and antifolates in pleural mesothelioma, patients are confronted with a need for second line treatment at relapse or progression. We conducted a systematic review of the literature for the activity, effectiveness and toxicity of second line treatment. The results are presented according to the class of drugs: chemotherapy and targeted or biological agent.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Biological; Chemotherapy; Mesothelioma; Meta-analysis; Outcome; Second line; Targeted treatment; Treatment

Mesh：

Year:  2015        PMID： 26162564     DOI： 10.1016/j.lungcan.2015.06.018

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  12 in total

1.  Review of nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial.

Authors:  Pyng Lee
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 2.  New horizons from immunotherapy in malignant pleural mesothelioma.

Authors:  Luana Calabrò; Giulia Rossi; Michele Maio
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

3.  Massive localized malignant pleural mesothelioma (LMPM): manifestations on computed tomography in 6 cases.

Authors:  Weigen Yao; Hanqing Yang; Guolai Huang; Yang Yan; Honglin Wang; Dongfang Sun
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma.

Authors:  Hannah L Moody; Michael J Lind; Stephen G Maher
Journal:  Mol Ther Nucleic Acids       Date:  2017-07-08       Impact factor: 8.886

Review 5.  Heterogeneity in Malignant Pleural Mesothelioma.

Authors:  Kathrin Oehl; Bart Vrugt; Isabelle Opitz; Mayura Meerang
Journal:  Int J Mol Sci       Date:  2018-05-30       Impact factor: 5.923

6.  Metastasis-associated gene 1 (MTA1) enhances cisplatin resistance of malignant pleural mesothelioma by ATR-Chk1-mediated DNA repair.

Authors:  Caihua Xu; Yufeng Hu; Bin Chen; Dapeng Li; Rongrui Liang; Meng Shen; Mengyao Wu; Min Tao
Journal:  Ann Transl Med       Date:  2021-04

Review 7.  Malignant pleural mesothelioma: an update.

Authors:  Glaucia N M Hajj; Carolina H Cavarson; Clóvis Antônio Lopes Pinto; Gabriela Venturi; João R Navarro; Vladmir C Cordeiro de Lima
Journal:  J Bras Pneumol       Date:  2021-12-13       Impact factor: 2.800

8.  Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study.

Authors:  Laura Saracino; Chandra Bortolotto; Stefano Tomaselli; Elia Fraolini; Matteo Bosio; Giulia Accordino; Francesco Agustoni; David M Abbott; Emma Pozzi; Dimitrios Eleftheriou; Patrizia Morbini; Pietro Rinaldi; Cristiano Primiceri; Andrea Lancia; Patrizia Comoli; Andrea R Filippi; Giulia M Stella
Journal:  BMC Cancer       Date:  2021-07-01       Impact factor: 4.430

9.  Expression and therapeutic significance of estrogen receptor β in malignant pleural mesothelioma.

Authors:  Giulia Pinton; Laura Moro
Journal:  Future Sci OA       Date:  2017-02-17

10.  DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.

Authors:  Hui Wang; Yu-Yuan Dai; Wen-Qian Zhang; Ping-Chih Hsu; Yi-Lin Yang; Yu-Cheng Wang; Geraldine Chan; Alfred Au; Zhi-Dong Xu; Shu-Juan Jiang; Wei Wang; David M Jablons; Liang You
Journal:  Int J Oncol       Date:  2017-05-26       Impact factor: 5.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.